174 related articles for article (PubMed ID: 18668131)
1. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
[TBL] [Abstract][Full Text] [Related]
2. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.
van de Donk NW; Palumbo A; Johnsen HE; Engelhardt M; Gay F; Gregersen H; Hajek R; Kleber M; Ludwig H; Morgan G; Musto P; Plesner T; Sezer O; Terpos E; Waage A; Zweegman S; Einsele H; Sonneveld P; Lokhorst HM;
Haematologica; 2014 Jun; 99(6):984-96. PubMed ID: 24658815
[TBL] [Abstract][Full Text] [Related]
4. What is the significance of monoclonal gammopathy of undetermined significance?
Atkin C; Richter A; Sapey E
Clin Med (Lond); 2018 Oct; 18(5):391-396. PubMed ID: 30287433
[TBL] [Abstract][Full Text] [Related]
5. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A; Ferrari F; Freeman SS; Redd R; El-Khoury H; Perry J; Patel V; Kaur P; Barr H; Lee DJ; Lightbody E; Downey K; Argyelan D; Theodorakakou F; Fotiou D; Liacos CI; Kanellias N; Chavda SJ; Ainley L; Sandecká V; Pospíšilová L; Minarik J; Jungova A; Radocha J; Spicka I; Nadeem O; Yong K; Hájek R; Kastritis E; Marinac CR; Dimopoulos MA; Get G; Trippa L; Ghobrial IM
Lancet Haematol; 2023 Mar; 10(3):e203-e212. PubMed ID: 36858677
[TBL] [Abstract][Full Text] [Related]
6. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.
El-Masri BM; Leka B; Mustapha F; Gundesen MT; Hinge M; Lund T; Andersen TL; Diaz-delCastillo M; Jafari A
Oncotarget; 2024 Jan; 15():20-26. PubMed ID: 38227739
[TBL] [Abstract][Full Text] [Related]
8. Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma.
Gonsalves WI; Broniowska K; Jessen E; Petterson XM; Bush AG; Gransee J; Lacy MQ; Hitosugi T; Kumar SK
Sci Rep; 2020 Jun; 10(1):10250. PubMed ID: 32581232
[TBL] [Abstract][Full Text] [Related]
9. Multimorbidity in patients with monoclonal gammopathy of undetermined significance.
Epstein MM; Zhou Y; Castaneda-Avila MA; Cohen HJ
Int J Cancer; 2023 Jun; 152(12):2485-2492. PubMed ID: 36799553
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of monoclonal gammopathy of undetermined significance in Shenzhen, China.
Xu A; Guo T; Zhang S; Luo H; Shen M; Ye Y; Ji L
Hematology; 2024 Dec; 29(1):2352686. PubMed ID: 38819332
[TBL] [Abstract][Full Text] [Related]
11. A gene signature can predict risk of MGUS progressing to multiple myeloma.
Sun F; Cheng Y; Ying J; Mery D; Al Hadidi S; Wanchai V; Siegel ER; Xu H; Gai D; Ashby TC; Bailey C; Chen JR; Schinke C; Thanendrarajan S; Zangari M; Janz S; Barlogie B; Van Rhee F; Tricot G; Shaughnessy JD; Zhan F
J Hematol Oncol; 2023 Jun; 16(1):70. PubMed ID: 37386588
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.
Lee DJ; El-Khoury H; Tramontano AC; Alberge JB; Perry J; Davis MI; Horowitz E; Redd R; Sakrikar D; Barnidge D; Perkins MC; Harding S; Mucci L; Rebbeck TR; Ghobrial IM; Marinac CR
Blood Adv; 2024 Apr; 8(7):1737-1746. PubMed ID: 38212245
[TBL] [Abstract][Full Text] [Related]
13. Mortality in the US Populations With Monoclonal Gammopathy of Undetermined Significance.
Ji M; Huber JH; Schoen MW; Sanfilippo KM; Colditz GA; Wang SY; Chang SH
JAMA Oncol; 2023 Sep; 9(9):1293-1295. PubMed ID: 37498610
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Survival Among Hispanics Living in Puerto Rico.
Castañeda-Avila MA; Ramos TS; Torres-Cintrón CR; Gierbolini-Bermúdez A; Tortolero-Luna G; Ortiz-Ortiz KJ
J Registry Manag; 2023; 50(4):167-169. PubMed ID: 38504710
[No Abstract] [Full Text] [Related]
15. Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma.
Murdaca G; Allegra A; Paladin F; Calapai F; Musolino C; Gangemi S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445745
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights.
Tentolouris A; Ntanasis-Stathopoulos I; Gavriatopoulou M; Andreadou I; Terpos E
J Cardiovasc Dev Dis; 2023 Dec; 10(12):. PubMed ID: 38132652
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal gammopathy of increasing significance: time to screen?
Chen LY; Drayson M; Bunce C; Ramasamy K
Haematologica; 2023 Jun; 108(6):1476-1486. PubMed ID: 36373250
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
Seth S; Zanwar S; Vu L; Kapoor P
Curr Hematol Malig Rep; 2020 Apr; 15(2):45-55. PubMed ID: 32222885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
